12:00 AM
Jan 28, 2016
 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Chemokine CC motif ligand 7 (CCL7; MCP3; SCYA6); CC chemokine receptor 3 (CCR3; CD193)


INDICATION: Prostate cancer

Patient sample, cell culture and mouse studies suggest inhibiting CCL7-CCR3 signaling could help treat prostate cancer. In patients with prostate cancer, tumor levels of CCR3 correlated with disease...

Read the full 135 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >